Study of Biochemical Parameters in Sera of Diabetes Mellitus DM (Type 1) Patients with Nephropathy and Myocardial Vascular Disease Complication

Perry H. Saifullah*, Saad Mohammed Nida** and Israa Burhan Raoof***
* Department of Chemistry, College of Science for Women, University of Baghdad.
** Department of Biotechnology, Biotechnology Research Center, Al-Nahrian University.
*** Department of Clinical Lab Science, College of Pharmacy, Al-Mustansiriyah University.

Abstract

Type 1 diabetes mellitus is a disease caused by the progressive and selective destruction, by autoimmune mechanisms, of pancreatic beta cells. The aim of this study was to detecting antibodies against DNA in Type 1 Diabetes mellitus DM patients with nephropathy and myocardial vascular disease complication the Study was done of 80 samples of blood and serum of woman were obtained under fasting conditions and they divided as:20 samples of patients of DM, DM with CV, DM with Nephropathy and Subjects as control group in National Diabetes Center (NDC), with average age about (13-67) years to measure level of lipid, urea, glucose-6-phosphate dehydrogenase. The study showed elevated in level of lipid profile, urea in patients, auto immune antibody compared with control group

Keywords: diabetes mellitus disease, autoantibody, ELISA.

Introduction

Diabetes mellitus, a common metabolic disorder resulting from defects in insulin secretion or action or both, is characterized by hyperglycemia often accompanied by glycosuria, polydipsia, and polyuria [1]. Type I (insulin-dependent) diabetes mellitus is caused by an autoimmune process that leads to inappropriate inflammation directed at the pancreatic islets [2]. It fact that Type I diabetes results from an autoimmune disease tells us that beta-cell destruction can be stopped by arresting the inflammatory autoimmune process [3]. Anti-DNA antibodies were found in the sera of diabetes mellitus patients and their presence was also related to the duration of diabetes mellitus and its complications [4]. Anti single strand DNA antibodies were also found in the sera of the patients of type 1 diabetes mellitus [5]. Diabetes produces disturbances of lipid profiles, especially an increased susceptibility to lipid peroxidation [6] which is responsible for increase incidence of atherosclerosis [7], a major complication of diabetes mellitus [8]. Diabetic nephropathy is the kidney disease that occurs as a result of diabetes. Cardiovascular and renal complications share common risk factors. The chronic hyperglycemia of diabetes is associated with long-term damage, dysfunction and failure of various organs, especially the eyes, kidneys, nerves, heart and blood vessels. Diabetes affects the kidney in stages. At the onset of diabetes, the kidney grows large and the glomerular filtration rate (GFR) becomes disturbed. Most recent basic and clinical research has pointed toward sclerosis and kidney failure [9].

Subjects, Instruments, Materials and Methods

Subjects: Include eighty (80) samples of female were divided as
A-Patients:
- DM without Cardiovascular.
- nephropathy Complications Group: consists of 20 patients.
- DM with Cardiovascular Complications Group: consists of 20 patients
- DM with Nephropathy (NP) Complications: consists of 20 patients.

B-Controls:
Twenty healthy subjects were included in this study as control group. None of the controls were diabetic, alcoholic, smoker, or having a history of coronary heart disease, thyroid or other metabolic disease before taking part in this study Type (1).
Their age range was (13-67) years, they were gender and age matched to that of type1 diabetes mellitus. A questionnaire was designed with different questions including duration of diabetes mellitus, family history,
usage of drugs, drug duration, height, weight, heart disease, and controls group. All diabetic patients with and without cardiovascular and nephropathy complications were treated with insulin injection. Diabetic patients were examined by an endocrinologist in National Diabetes Center (NDC). Patients with thyroid function disease, and hormonal abnormalities were excluded from the study. Patients and controls were classified according to the following:

Table (1)
Distribution of study Participant according to the Health's status and Age range.

<table>
<thead>
<tr>
<th>Groups</th>
<th>No.</th>
<th>Age range (Years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>DM without complications</td>
<td>20</td>
<td>24-50</td>
</tr>
<tr>
<td>DM with CV complications</td>
<td>20</td>
<td>22-66</td>
</tr>
<tr>
<td>DM with NP complications</td>
<td>20</td>
<td>13-67</td>
</tr>
<tr>
<td>Controls</td>
<td>20</td>
<td>17-65</td>
</tr>
</tbody>
</table>

Instruments

Table (2)

<table>
<thead>
<tr>
<th>Instruments</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>spectrophotometer</td>
<td>Cencil</td>
</tr>
<tr>
<td>centrifuge</td>
<td>Hettachi</td>
</tr>
<tr>
<td>Incubator</td>
<td>memert</td>
</tr>
<tr>
<td>ELISA: Microplate Reader Model</td>
<td>Bio-RAD</td>
</tr>
</tbody>
</table>

Statistical and analysis

Using ANOVA Test, Significant using Students-t-test for two independent means at 0.05 level of significance.

Principle: Serum autoimuno antibody was determined to quantitative and qualitative detection of IgG, IgA and IgM antibodies against DNA in human serum (AESKULISA Company, Germany[^10].

Materials and Methods

Determination of Serum Level of autoimuno antibody

- Kit Contents

<table>
<thead>
<tr>
<th>Item</th>
<th>Reagent</th>
<th>Materials</th>
<th>Preparation</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>1. Sample Buffer Concentrate</td>
<td>(tris, Nacl, Tween20, sodiumazide)</td>
<td>Dilute the concentrated sample buffer 1:5 with distilled water</td>
</tr>
<tr>
<td>B</td>
<td>2. Wash Buffer Concentrate</td>
<td>(tris, Nacl, Tween20, sodiumazide)</td>
<td>Dilute the concentrated wash buffer 1:50 with distilled water</td>
</tr>
<tr>
<td>C</td>
<td>3. Negative control Human serum, sodium azide</td>
<td></td>
<td>Ready to use</td>
</tr>
<tr>
<td>D</td>
<td>4. Positive control Human serum, sodium azide</td>
<td></td>
<td>Ready to use</td>
</tr>
<tr>
<td>E</td>
<td>5. Cut-off calibrator Human serum, sodium azide</td>
<td></td>
<td>Ready to use</td>
</tr>
<tr>
<td>F</td>
<td>6. Calibrators Human serum, sodium azide</td>
<td></td>
<td>Ready to use</td>
</tr>
<tr>
<td>G</td>
<td>7. Conjugate Anti-human conjugated with horseradish peroxide</td>
<td></td>
<td>Ready to use</td>
</tr>
<tr>
<td>H</td>
<td>8. TMB substrate</td>
<td></td>
<td>Ready to use</td>
</tr>
<tr>
<td>I</td>
<td>9. Stop Solution (hydrochloric acid)</td>
<td></td>
<td>Ready to use</td>
</tr>
<tr>
<td>N</td>
<td>10. Microtiterplate 12x8 wellstrips with break away microwells</td>
<td>96 wells (12 strips x 8 wells)</td>
<td></td>
</tr>
</tbody>
</table>

Assay Procedure

The assay was carried out following the instructions in the kit’s leaflet, which are summarized in the following steps:

1. Samples were diluted before starting with the test procedure. Dilute sample buffer 1:5 with distilled water according to the following scheme: Dilution: 20 µl sample buffer + 80µl distilled water.
2. Dilute wash buffer 1:50 with distilled water according to the following scheme:
Dilution: 20 µl wash buffer + 980 µl distilled water.

3. Dilute serum 1:50 with sample Buffer (1x) according to the following scheme: Dilution: 10 µl sample + 1000 µl sample Buffer (1x).

4. The microwell strips were washed twice with approximately 300 µl Wash Buffer per well. The Wash Buffer was allowed to sit in the wells for about 20 seconds. Discard liquid from wells inverting the plate. The microwell strips were used immediately after washing.

5. Pipette (100 µl) of diluted serum into microwells.

6. Pipette (100 µl) calibrators or cut-off calibrators and negative and positive controls into microwells.

7. Incubated at (20° to 32°C) for 30 min.

8. Strips were washed 3 time with 300 µl wash buffer dilution.

9. An aliquot (100 µl) of diluted conjugate was added to all wells, including the blank wells.

10. Incubated at (20° to 30°C) for 30 min.

11. The microwell strips were washed 3 times with 300 µl wash buffer dilution.

12. An aliquot (100 µl) of TMB Substrate Solution was pipette to all wells.

13. The microwell splate were incubated at (20° to 32°C) for about 30 min.

14. The enzyme reaction was stopped by quickly pipetting 100 µl of Stop Solution into each well.

15. The absorbance was read of each microwell on spectrophotometer using 450 nm as the primary wavelength.

**Determination of Serum Glucose**

By using an enzymatic colorimetric method with a commercially available kit, the fasting plasma glucose (FPG) was determined according to Scheme (1).

**Determination of Serum Total Cholesterol (S.T.C.)**

Serum cholesterol is measured by cholesterol kit, using an enzymatic method based on the following reactions [12]: according to Scheme (2).

**Determination of Serum Triacylglycerol (S.TAG)**

Serum triacylglycerol is measured by triacylglycerol kit, using an enzymatic method based on the following reactions [13]: according to Scheme (3).

**Determination of Serum High Density Lipoprotein-Cholesterol (S.HDL-C)**

Serum HDL-C is measured by HDL-C kit, using the method of Burstein et al., 1980 [14].

**Determination of Serum Low Density Lipoprotein-Cholesterol (S.LDL-C)**

LDL-cholesterol is very difficult to isolate and measure. Hence, LDL level is most usually derived by the friedwals formula as follows [15].

\[
LDL\text{-cholesterol} = \text{Total cholesterol} - \left[\text{HDL-cholesterol} + \frac{\text{TG}}{5}\right]
\]

**Determination of Serum S.VLDL-C**

Very low-density lipoprotein- cholesterol was estimated by using formula of friedwald [16] VLDL-Ch = TG/5.

**Determination of Serum Urea**

Enzymatic determination of urea concentration (urease modified Berthelot reaction [17], urease hydrolysis urea by product ammonium: according to Scheme (4).
Glucose + O₂ + H₂O \rightarrow \text{Gluconic acid + H₂O₂}

2H₂O₂ + 4-aminoantipyrine + phenol \rightarrow \text{Quinonimine + 4H₂O}

\text{Scheme (1)}

\text{Cholesterol esterase}

\text{Cholesterol ester} \rightarrow \text{Cholesterol + Fatty acids}

\text{Cholesterol oxidase}

\text{Cholesterol} \rightarrow \text{Cholest-4-en-3-one + H₂O₂}

2H₂O₂ + Phenol + 4-aminoantipyrine \rightarrow \text{Quinoneimine + 4H₂O}

\text{Scheme (2)}

\text{Triacylglycerol} \rightarrow \text{Glycerol + fatty acids}

\text{glycerokinase}

\text{Glycerol + ATP} \rightarrow \text{Glycerol-3-phosphate + ADP}

\text{oxidase}

\text{Glycerol-3-phosphate} \rightarrow \text{Dihydroxyacetone phosphate + H₂O₂}

\text{Peroxidase}

\text{H₂O₂ + 4-Chlorophenol + 4-Aminoantipyrine} \rightarrow \text{Quinoneimine + 4H₂O}

\text{Scheme (3)}

\text{Urea + H₂O} \rightarrow \text{2NH₃ + CO₂}

\text{urease}

\text{NH₄⁺ + salsylate + hypochloride} \rightarrow \text{indophenol}

\text{Scheme (4)}

\text{Result}

The means (±SD) of age are shown in Table (3). In all patient groups, the means of age were greater than in the control subjects. In addition, there was significant difference (p=0.01) between the means of age in DM patients and control groups. Also the means (±SD) of DM duration are shown in Table (3). There was no significant difference between the means of duration in DM with/without complications compared with control groups as shown in Table (3) and Fig.(1).
Data demonstrated by Table (4) shows total serum cholesterol levels were significantly (p=0.04) higher in DM patients when compared with controls (154 ± 30.3 mg/dl) Vs. (157.05 ± 28.4 mg/dl) for DM patients and controls respectively.

Total serum cholesterol in DM with nephropathy patients and DM with CV patients was (182.9 ± 45.6 mg/dl) and (238.5 ± 44.9 mg/dl) there was no significant difference (P>0.05) could be detected compared to mean control (154 ± 30.3) as shown in Table (4) and Fig.(2).

Table (3)
Mean of Fasting blood sugar, age, duration of Diabetes Mellitus in DM groups compared to control groups.

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>DM without complications</th>
<th>DM with nephropathy</th>
<th>DM with Vascular disease</th>
<th>P.value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Valid N</td>
<td>20</td>
<td>20</td>
<td>20</td>
<td>20</td>
<td>-</td>
</tr>
<tr>
<td>Age (year)</td>
<td>33.65±6.3</td>
<td>43.45±16.14</td>
<td>50.65±13.56</td>
<td>51±12.06</td>
<td>0.01</td>
</tr>
<tr>
<td>Duration of DM</td>
<td>-</td>
<td>6.5±5.13</td>
<td>7.45±5.32</td>
<td>8.4±5.69</td>
<td>0.6</td>
</tr>
<tr>
<td>Mean±SD FBG(mg/dl)</td>
<td>88.63±8.47</td>
<td>229.05±91.63</td>
<td>231.1±97.84</td>
<td>241.1±105.51</td>
<td>0.9</td>
</tr>
</tbody>
</table>

Figure (1) The mean of serum Glucose level (mg/dl) in Diabetes Mellitus groups and control groups.

Table (4).

<table>
<thead>
<tr>
<th>Mean±SD</th>
<th>Controls</th>
<th>DM without complications</th>
<th>DM with nephropathy</th>
<th>DM with CV complications</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>S.cholesterol (mg/dl)</td>
<td>154 ± 30.3</td>
<td>157.05±28.4</td>
<td>182.9±45.6</td>
<td>238.5±44.9</td>
<td>0.04</td>
</tr>
<tr>
<td>Triglycerid (mg/dl)</td>
<td>96.88±21.3</td>
<td>106±41.5</td>
<td>142.6±58.2</td>
<td>198±102.8</td>
<td>0.004</td>
</tr>
<tr>
<td>HDL (mg/dl)</td>
<td>51.62±2.95</td>
<td>50.5±5.6</td>
<td>45.68±6.07</td>
<td>40.7±5.68</td>
<td>0.0008</td>
</tr>
<tr>
<td>LDL (mg/dl)</td>
<td>77.29±24.72</td>
<td>82.6±28.3</td>
<td>100.7±50.7</td>
<td>153.7 ±44.3</td>
<td>0.08</td>
</tr>
<tr>
<td>VLDL (mg/dl)</td>
<td>20±5.09</td>
<td>24.8±15.2</td>
<td>28.15±11.8</td>
<td>42.6±21.53</td>
<td>0.01</td>
</tr>
<tr>
<td>Atherogenic Index (LDL/HDL)</td>
<td>1.53±0.54</td>
<td>1.58±0.55</td>
<td>2.15±1.37</td>
<td>3.82±1.17</td>
<td>0.08</td>
</tr>
<tr>
<td>LDL Size Index (TG/HDL)</td>
<td>1.91±0.81</td>
<td>2.1±1.06</td>
<td>3.29±1.71</td>
<td>5.21±3.03</td>
<td>0.003</td>
</tr>
</tbody>
</table>

Lipid profile in Diabetes Mellitus groups compared to control groups.
Fig. (2) The mean of serum S.cholesterol level (mg/dl) in Diabetus Mellitus groups and control groups.

Triglyceride was found to be significantly higher (p=0.004) in DM patients with means of (106±41.5 mg/dl) compared to control with a mean of (96.88±21.3 mg/dl). serum Triglyceride In DM with nephropathy patients and DM with CV patients was (142.6±58.2mg/dl) and (198±102.8mg/dl) there was no significant difference (P>0.05) could be detected compared to control as shown in Table (4) and Fig.(3).

Fig. (3) The mean of serum Tri Glyceride level (mg/dl) in Diabetus Mellitus groups and control groups.

The mean serum level of HDL-cholesterol slightly decrease in the DM patients (50.5±5.6 mg/dl) when compared to that found in the control group (51.62±2.95mg/dl) but the difference was not significant (P>0.05) while in DM with nephropathy patients and DM with CV patients ((45.68±6.07mg/dl) and (40.7±5.68mg/dl) when compared to control as shown in table (4) and Fig. (4).

Fig. (4) The mean of serum High density lipoprotein level (mg/dl) in Diabetus Mellitus groups and control groups.

LDL-cholesterol levels were not significantly (p=0.08) higher in DM patients (82.6±28.3mg/dl) vs. (77.29±24.72mg/dl) for
DM patients and controls respectively as shown in Fig.(4), while in DM with nephropathy patients and DM with CV patients (100.7±50.7mg/dl) and (153.7±44.3mg/dl) no significant difference (P>0.05) when compared to control as shown in Table (4) and Fig. (5).

Fig. (5) The mean of serum Low density lipoprotein level (mg/dl) in Diabetus Mellitus groups and control groups.

There was not significant (p=0.01) difference in mean VLDL-cholesterol (24.8±15.2mg/dl) in DM patients than in the control group (20±5.09mg/dl). Table (4) also show no a significant difference (P>0.05) between in DM with nephropathy patients and DM with CV patients (28.15±11.8mg/dl) and (42.6±21.53mg/dl) when compared with control show in Fig. (6).

Fig. (6) The mean of serum Very low density lipoprotein level (mg/dl) in Diabetus Mellitus groups and control groups.

This study reveals increased levels of TC, TAG, LDL-C, and decreased levels of HDL-C compared with control showed that female diabetic patients had significantly higher levels of cholesterol, Hyperlipidemia in females may be attributed to the effects of sex hormones on body fat distribution, leading to differences in altered [18]. Also High HDL levels protect against CV development, as patients with high HDL tend to have lower prevalence of CV risk factors. On the other hand, patients with low levels of HDL are more likely to develop CV disease [19]. The serum Serum Atherogenic mean LDL/HDL values were (1.58±0.55) for DM and control patients (1.53±0.54) as shown in Fig.(7). Serum Atherogenic value were found to be not significantly elevated in DM with nephropathy patients level (2.15±1.37) patients group and also the mean of DM with vascular disease (3.82±1.17) compared to control, Table (4) Fig.(7), Serum Atherogenic LDL-C/HDL-C ratio value were found to be elevated in diabetes mellitus patients as compared with control, Several large clinical studies have found the LDL-C/HDL-C ratio to be an excellent predictor of CV risk [20].
The means of Atherogenic Index Serum TG/HDL-C are shown in Table (4), Fig. (8). In mean DM patient (2.1±1.06), the means of Serum LDLs were significantly (p=0.003) than in mean control, (1.9±0.81) subjects, There was not significant difference between the means of DM with nephropathy patients (3.29±1.71) with the mean of control (1.91±0.81), also the mean of DM with vascular disease (5.21±3.03) not significantly (p=0.9) when compared with to mean controls (1.91±0.81). Also serum of Atherogenic Index TG/HDL show increase in mean of DM patient compared with control [21]. The presence of hypertriglyceridemia, low HDL-C concentrations, and high TG/HDL-C ratio associated with insulin resistance because insulin affects TAG and HDL-C metabolism [22].

BMI was found to be significantly [p=0.03] in DM patients with a mean of (29.28±7.22 Kg/m²) compared to controls with a mean of (24.19±2.57 Kg/m²), and a significant difference was found (p=0.01) between DM with nephropathy patients (28.25±4.14 Kg/m²) and control (24.19±2.57Kg/m²), also significant difference (p=0.0005) was found between DM with vascular patients (31.53±6.22Kg/m²) and mean control (24.19±2.57Kg/m²) as shown in Table (5), Fig. (9) BMI was found increased in DM patients with a mean of compared to controls Although BMI is a measure of overall adiposity, it is often considered an indicator of body fatness; it is a surrogate measure of body fat because it measures excess weight rather than excess fat [23].
Table (5)
Mean of Body Mass Index (BMI) in Diabetus Mellitus groups compared to control groups.

<table>
<thead>
<tr>
<th>Mean±SD</th>
<th>Controls</th>
<th>DM without complications</th>
<th>DM with nephropathy</th>
<th>DM with CV complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMI (Kg/m²)</td>
<td>24.19±2.57</td>
<td>29.28±7.22</td>
<td>28.25±4.14</td>
<td>31.53±6.22</td>
</tr>
<tr>
<td>P.Value compared with control</td>
<td>-</td>
<td>0.03</td>
<td>0.01</td>
<td>0.0005</td>
</tr>
</tbody>
</table>

Fig. (9) The mean of Body Mass Index (BMI) level (mg/dl) in Diabetus Mellitus groups and control groups.

The means (±SD) of Percent Body Fat (PBF) are shown in Table (6). In all patient groups, the means of PBF were greater than in the control subjects. There was significant difference (p=0.0008) between the means of PBF in DM patients (40.14±10.58) with the mean of control (30.13±5.67) The mean of DM with nephropathy patients level (40.16±6.08) was not significantly (p=0.9) as compared to mean controls (30.13±5.67), also the mean of DM with vascular disease (44.50±7.86) not significantly (p=0.9) when compared with to mean controls 30.13±5.67) shown in Table (6) Fig. (10).

In all patient groups, the means of PBF were greater than in the control subjects Clinical evidence suggests that the association of diabetes with central obesity is stronger than the association with general fat. Central obesity has been associated with decreased glucose tolerance, reduced metabolic clearance of insulin, and decreased insulin-stimulated glucose disposal. With the rapidly increasing diabetic population in our country [24].
Table (6)
Mean Percent Body Fat (PBF) in Diabetus Mellitus groups compared to control groups.

<table>
<thead>
<tr>
<th></th>
<th>Controls</th>
<th>DM without complications</th>
<th>DM with nephropathy</th>
<th>DM with CV complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>PBF</td>
<td>30.13±5.67</td>
<td>40.14±10.58</td>
<td>40.16±6.08</td>
<td>44.50±7.86</td>
</tr>
<tr>
<td>P. Value compared with control</td>
<td>-</td>
<td>0.0008</td>
<td>0.9</td>
<td>0.9</td>
</tr>
</tbody>
</table>

Fig. (10) The mean of Percent Body Mass (PBF) level (mg/dl) in Diabetus Mellitus groups and control groups.

Autoantibody was found to be significantly [p=0.02] in DM patients with a mean of (0.32±0.12) compared to controls with a mean of (0.24±0.04), and a significant difference was found (p=0.0007) between DM with nephropathy patients (0.34±0.1) and control (0.25±0.05), also not significant difference (p=0.1) was found between DM with vascular patients (0.27±0.07) and mean control (0.24±0.04) as shown in Table (7), Fig. (11).

Table (7)
Mean of Autoantibody in Diabetus Mellitus groups compared to control groups.

<table>
<thead>
<tr>
<th>ELISA (U/ml)</th>
<th>Control</th>
<th>DM without complications</th>
<th>DM with Nephropathy complication</th>
<th>DM with CV complication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Valid N</td>
<td>20</td>
<td>20</td>
<td>20</td>
<td>20</td>
</tr>
<tr>
<td>Mean±SD</td>
<td>0.24±0.04</td>
<td>0.32±0.12</td>
<td>0.34±0.1</td>
<td>0.27±0.07</td>
</tr>
<tr>
<td>P value compared with control</td>
<td>-</td>
<td>0.02</td>
<td>0.0007</td>
<td>0.1</td>
</tr>
</tbody>
</table>

In addition of that the disruption of insulin synthesis is caused by immunological destruction of the islet cells by autoantibodies in IDDM patient. Immunological Autoantibody was found to increased in DM patients compared to control [25].
Urea was found to be significantly [p=0.02] in DM patients with a mean of (26.25±3.84) compared to controls with a mean of (23.25±4.03), and a significant difference was found (p=0.01) between DM with nephropathy patients (41.9±6.07) and control (23.25±4.03), also significant difference (p=0.005) was found between DM with vascular patients (26.6±2.92) and mean control (23.25±4.03) as shown in Table (8), Fig. (12), in the present investigation, diabetes associated nephropathy (DM+NP) Clinical abnormalities are often detected 5–10 years after onset or diagnosis of DM. The patient to be Nephropathy DM [26].

### Table (8)

<table>
<thead>
<tr>
<th>Urea(mg/ml)</th>
<th>Control</th>
<th>DM without complications</th>
<th>DM with nephropathy disease</th>
<th>DM with CV disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Valid N</td>
<td>20</td>
<td>20</td>
<td>20</td>
<td>20</td>
</tr>
<tr>
<td>Mean±SD</td>
<td>23.25±4.03</td>
<td>26.25±3.84</td>
<td>41.9±6.07</td>
<td>26.6±2.92</td>
</tr>
<tr>
<td>P value compared with control</td>
<td>0.02</td>
<td>0.01</td>
<td>0.005</td>
<td></td>
</tr>
</tbody>
</table>

Fig. (11) The mean of Autoantibody level (mg/dl) in Diabetus Mellitus groups and control groups.

Fig. (12) The mean of serum Urea level (mg/dl) in Diabetus Mellitus groups and control groups.
References


الخلاصة

داء السكري من النوع الأول هو مرض سببه تحطم المضادات الاعتيادية ومتقدم خلايا في البنكرياس عن طريق ميكانيكية ذاتية المناعة، الدراسات الأخيرة تدعم هذه الصفة الذاتية المناعة في داء السكري من النوع الأول. الهدف من الدراسة هو الكشف عن الأجسام المضادة من النوع الأول لمرضى السكري مع اضطرابات الكلوية والوعائية حيث أجريت الدراسة على 80 عينة من النساء والدم من النساء وقد تم تقسيمهم كالآتي: 20 عينة للمريض المصاب بالسكري مع الامراض الوعائية و 20 عينة الدم للمريض المصاب بالسكري مع اضطرابات الكلوية و 20 عينة الدم للمريض المصاب بالسكري مع اضطرابات الكلوية و 20 عينة الدم للمريض المصاب بالسكري.

الانثطراق الوعائي و الامراض الكلوية و الانتصاف السريري و الانتقائية الموجودة في المركز الوطني لبحث الأمراض الوعائية. لاحظ أن المرضى الذين يعانون من=node (12-37) سنة وذلك لقياس مستوى اليوريا والدهون والاجسام المضادة. اظهرت النتائج وجود ارتفاع في مستوى اليوريا والدهون وكمية الأجسام المضادة لمرضى السكري من النوع الأول مقارنة بمجموعة الاصحاب (مجموعة التحكم).